s-3304
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2001 (NCT00033566)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- 72 kDa type IV collagenaseINHIBITOR
MMP2 inhibitor
- Matrix metalloproteinase 9INHIBITOR
MMP9 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(C#Cc2ccc(S(=O)(=O)N[C@H](Cc3c[nH]c4ccccc34)C(=O)O)s2)cc1- Mol. weight
- 464.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL297792 ↗
Also known as
- s 3304
- s-3304
- s-3304
- s-3304
- s-3304
- s3304 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00078390 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2003 | Shionogi |
| NCT00033215 | Phase 1 | Nov 1, 2001 | Shionogi |
| NCT00033566 | Phase 1 | Oct 1, 2001 | State University of New York, Buffalo |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shionogi | For profit | 2 | 2 | 2 | 2001 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2001 |
2 organizations
Page 1 / 1